EGFR and non-small cell lung carcinoma: For example, EGFR inhibitors are also utilized in treating non-small cell lung cancer (NSCLC), but there is a risk of developing resistance mutations, like T790M, which may necessitate subsequent rounds of treatment using new drugs [7].